Search

A study published in the journal Clinical & Translational Medicine presents a novel risk stratification model for detecting residual tumors in patients with non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumors (TURBT). The model is based on urinary DNA methylation and incorporates clinical features such as tumor grade, presence of multiple tumors, maximum tumor size, histologic variants, and lymphatic-vascular invasion. The study found that the model achieved high accuracy in detecting residual tumors, with a sensitivity of 95.83%. By accurately identifying high-risk patients, unnecessary re-TURBT procedures can be reduced, thereby reducing patient distress and associated costs. [Extracted from the article]